

Paclitaxel as albuminbound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal)

Technology appraisal guidance Published: 28 October 2015

www.nice.org.uk/guidance/ta362

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

Contents

Advice	3
Background	4
Information	5

Paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer (terminated appraisal) (TA362)

Advice

NICE is unable to make a recommendation about the use in the NHS of paclitaxel as albumin-bound nanoparticles with carboplatin for adults with untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable, because no evidence submission was received from Celgene for the technology.

Background

Celgene was invited to submit evidence for this single technology appraisal for paclitaxel as albumin-bound nanoparticles in September 2015.

The company stated that it does not intend to launch paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable, in the UK.

NICE has therefore terminated this single technology appraisal.

Information

NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of paclitaxel as albumin-bound nanoparticles with carboplatin for adults with untreated non-small-cell lung cancer when potentially curative surgery or radiation therapy or both are unsuitable. If, after doing this, organisations still wish to consider paclitaxel as albumin-bound nanoparticles with carboplatin for untreated non-small-cell lung cancer, they should follow the advice on rational local decision-making in the <u>NHS Constitution for England</u> and the <u>NHS Commissioning Board and Clinical Commissioning Groups</u> (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable.

NICE will review the position at any point if the company indicates that it wishes to make a full submission.

Copyright

© National Institute for Health and Care Excellence 2015. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.

ISBN: 978-1-4731-1510-1